Study of HWK-016 for advanced ovarian or endometrial cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called HWK-016, which is designed to target and deliver medicine directly to cancer cells that have a specific marker (MUC16). It is for people with advanced ovarian or endometrial cancer to see if it can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have either endometrial cancer or ovarian cancer that is advanced (has spread or cannot be surgically removed).
- You cannot have cancer that has spread to your brain and is not under control, or a history of a specific type of brain lining cancer called carcinomatous meningitis.
- You must not have any active serious infections, such as bacterial, viral, fungal, or parasitic infections.
- Your eyes must be healthy—no cornea damage, cornea transplant, or ongoing corneal disease.
- You should have no serious heart disease, a normal heart rhythm (QTcF less than 470 ms), and no history of pneumonitis or lung scarring.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HWK-007, which is designed to target and attack cancer cells while sparing healthy ones. It is for people with specific advanced solid tumors (lung, endometrial, or ovarian cancer) that have not responded well to standard treatments.
This trial tests a new immunotherapy drug (QL1706) for people with advanced endometrial cancer whose previous immunotherapy stopped working. It aims to see if this different approach can help when standard treatments have failed.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a new drug called MRG007 for people with advanced solid tumors that haven't responded to other treatments. The drug targets a protein called CDH17 on cancer cells; you need a tumor sample to check for it.
This trial tests a new drug called ABBV901, given alone or with other anticancer drugs, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and how it affects the body.
Hear when a new Platinum-resistant Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.